The customer observed multiple false positive cardiac troponin-i while using architect stat troponin-i reagents.The following data was provided for the same patient.The customer uses normal range less than 0.06 ng/ml, abnormal range 0.06 to 0.19 ng/ml, and elevated greater than or equal to 0.2 ng/ml.Patient 1: sid (b)(4) ((b)(4) collected march 25, 2018 13:33) initial 0.213 ng/ml (positive), repeat 0.056 (negative), 0.198 (positive), 0.008, 0.00 ng/ml (negative).Sid 18-084-02206 (previous specimen, initial tested march 25, 2018) initial 0.02 ng/ml (negative), repeat 0.11 ng/ml (positive), 0.00 ng/ml (negative).Sid (b)(4) (initial tested march 25, 2018) initial less than 0.03 ng/ml (negative), repeat 0.000 ng/ml (negative).Patient 2: sid (b)(4) (collection and test date not provided) initial 0.213 ng/ml (positive), repeat 0.56 ng/ml (negative), 0.198 ng/ml (positive), 0.008 ng/ml (negative).No adverse impact to patient management was reported.
|
Evaluation of the customer issue included a review of the complaint text, a search for similar complaints, device history review, instrument log review, labeling review, and field data review.No adverse trend was identified for the customer issue.Device history review did not identify any issues that may have caused the customer issue.Log review did not identify any issues that contributed to the customer issue.Labeling was reviewed and found to be adequate.Review of field data showed the complaint lot patient median value was within established control limits and no unusual reagent performance was identified.Based on all available information and abbott diagnostics evaluation, no systemic issue was identified and no product deficiency was found.
|